Skip to content
← Full study record

NCT01843374 · MORE INFO

Limitations, agreements, and source contact

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the communication of results, it being understood that results shall be published regardless of outcome
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Baseline characteristics and efficacy outcomes are from the primary analysis reported in the main CSR based on a DCO of 24th January 2016. Participant flow and AE results are from the CSR Addendum based on a DBL of 23 January 2017.
point Of Contact
email
Paul.Stockman@astrazeneca.com
organization
AstraZeneca
phone
+44 162-523-1815
title
Paul Stockman, MD, PhD
Complete source fields
certain Agreement
other Details
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the communication of results, it being understood that results shall be published regardless of outcome
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Baseline characteristics and efficacy outcomes are from the primary analysis reported in the main CSR based on a DCO of 24th January 2016. Participant flow and AE results are from the CSR Addendum based on a DBL of 23 January 2017.
point Of Contact
email
Paul.Stockman@astrazeneca.com
organization
AstraZeneca
phone
+44 162-523-1815
title
Paul Stockman, MD, PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice